INDIA LIFE SCIENCES FUND IV DOMESTIC

Stage focus

Growth (Series C+)

Primary sector

Pharma & Life sciences

City

Hyderabad

HQ / office

Hyderabad, Telangana (Jubilee Hills)

Fund registered

2023

Investments on record

39

Corpus (as reported)

USD 850M+ AUM across 4 funds; India Life Sciences Fund IV ~USD 300-400M target (IFC committed $25M); IV ~$304M (2023 vintage)

Website

invascent.com

LinkedIn

Profile ↗

InvAscent is a Hyderabad-based growth-equity firm (founded 2005) providing growth capital to Indian life sciences and healthcare companies; India Life Sciences Fund IV is its fourth fund. It has made ~39 investments with ~20 exits across four funds.

Growth equity / growth-stage private equity in Indian life sciences and healthcare — pharma, healthcare delivery (hospitals), health-tech, medical devices, animal health

USD 10-50M average per portfolio company (per IFC disclosure for Fund IV)

As compiled from public sources — verify with the investor.

SEBI AIF Category II — reported as “Cat II”

• IN/AIF2/23-24/1403

None found — no SIDBI/FFS or Indian-government LP identified. Anchor/sole LP of Fund IV is IFC (International Finance Corporation, World Bank Group DFI; committed up to USD 25M, capped at 19.99%). IFC is a multilateral DFI, not an Indian government fund-of-funds.

SRV Hospitals; Geri Care; Maiva Pharma; ABI Health Technologies; Gland Pharma; Health Care Global (HCG); Dr. Agarwal's Health Care; Sutures India

Not disclosed on site; led by Hariharnath Buggana (Chairman & MD); small partner-led PE team (firm founded 2005)

Manager: Invascent ILSF Manager LLP (LLP under LLP Act 2008); LLP-managed Category II AIF; multi-fund life-sciences PE platform (Funds I-IV)

What does INDIA LIFE SCIENCES FUND IV DOMESTIC invest in?

Growth equity / growth-stage private equity in Indian life sciences and healthcare — pharma, healthcare delivery (hospitals), health-tech, medical devices, animal health

What cheque size does INDIA LIFE SCIENCES FUND IV DOMESTIC write?

As compiled from public sources: USD 10-50M average per portfolio company (per IFC disclosure for Fund IV)

How do I pitch INDIA LIFE SCIENCES FUND IV DOMESTIC through iHub India?

Create a free startup account, open a funding round, and send a structured pitch from this profile. If the investor accepts, contact details are shared and the conversation moves into a tracked deal room.

VC fund (Cat II)

108 Capital Venture Fund

Growth (Series C+) · Not disclosed · Bengaluru

Contact on file

Angel fund (Cat I)

1Funds Trust

Multi-stage · Pharma & Life sciences · Mumbai

Pre-seed to Series A+ stage; specific cheque size not disclosedContact on file

VC fund (Cat I)

35North India Growth Fund Trust

Growth (Series C+) · Fintech · Mumbai

Approx USD 0.5-3M (INR ~3-20 Cr) per company; 8-10 companies targeted (per inc42 / fund reporting)Contact on file

VC fund (Cat I)

3F Ventures

Early stage (Pre-Series A) · Pharma & Life sciences · Mumbai

Equity-free grants: Micro Grant INR 50k-1 Lakh; Indie Grant INR 10k-15k; wildcard stipend ~INR 10k/month (per own site). Not a conventional equity AIF chequeContact on file

VC fund (Cat II)

A91 Partners

Growth (Series C+) · Financial services (non-tech) · Mumbai

Typically USD 10M-50M per company (approx INR 80-400+ Cr), targeting ~15 companies per fund.Contact on file

VC fund (Cat II)

a99 Investment AIF Trust

Growth (Series C+) · Manufacturing & Industrials · Chennai

INR 20-80 Cr (pre-Series A to pre-Series B cheques, Fund III)Contact on file

All Growth (Series C+) investors →

• ⚑ PE / growth equity (Cat II), not early-stage startup VC

Compiled from SEBI registrations and public sources as of 2026-07. iHub India lists investors neutrally and does not endorse, rank, or verify investment terms — confirm all details directly with the investor before transacting.

Sources: https://invascent.com; https://disclosures.ifc.org/project-detail/SII/49742/india-life-sciences-fund-iv